TY - JOUR
T1 - The Risk of Recurrence in Endometrial Cancer Patients with Low-Volume Metastasis in the Sentinel Lymph Nodes: A Retrospective Multi-Institutional Study
AU - Buda, Alessandro
AU - Paniga, Cristiana
AU - Taskin, Salih
AU - Mueller, Michael
AU - Zapardiel, Ignacio
AU - Fanfani, Francesco
AU - Puppo, Andrea
AU - Casarin, Jvan
AU - Papadia, Andrea
AU - De Ponti, Elena
AU - Grassi, Tommaso
AU - Mauro, Jessica
AU - Turan, Hasan
AU - Vatansever, Dogan
AU - Gungor, Mete
AU - Ortag, Firat
AU - Imboden, Sara
AU - Garcia-Pineda, Virginia
AU - Mohr, Stefan
AU - Siegenthaler, Franziska
AU - Perotto, Stefania
AU - Landoni, Fabio
AU - Ghezzi, Fabio
AU - Scambia, Giovanni
AU - Taskiran, Cagatay
AU - Fruscio, Robert
PY - 2023
Y1 - 2023
N2 - The aim of this study was to assess the impact of low-volume metastasis (LVM) on disease-free survival (DFS) in women with apparent early-stage endometrial cancer (EC) who underwent sentinel lymph node (SLN) mapping. Patients with pre-operative early-stage EC were retrospectively collected from an international collaboration including 13 referring institutions. A total of 1428 patients were included in this analysis. One hundred and eighty-six patients (13%) had lymph node involvement. Fifty-nine percent of positive SLN exhibited micrometastases, 26.9% micrometastases, and 14% isolated tumor cells. Seventeen patients with positive lymph nodes did not receive any adjuvant therapy. At a median follow-up of 33.3 months, the disease had recurred in 114 women (8%). Patients with micrometastases in the lymph nodes had a worse prognosis of disease-free survival compared to patients with negative nodes or LVM. The rate of recurrence was significantly higher for women with micrometastases than those with low-volume metastases (HR = 2.61; p = 0.01). The administration of adjuvant treatment in patients with LVM, without uterine risk factors, remains a matter of debate and requires further evaluation.
AB - The aim of this study was to assess the impact of low-volume metastasis (LVM) on disease-free survival (DFS) in women with apparent early-stage endometrial cancer (EC) who underwent sentinel lymph node (SLN) mapping. Patients with pre-operative early-stage EC were retrospectively collected from an international collaboration including 13 referring institutions. A total of 1428 patients were included in this analysis. One hundred and eighty-six patients (13%) had lymph node involvement. Fifty-nine percent of positive SLN exhibited micrometastases, 26.9% micrometastases, and 14% isolated tumor cells. Seventeen patients with positive lymph nodes did not receive any adjuvant therapy. At a median follow-up of 33.3 months, the disease had recurred in 114 women (8%). Patients with micrometastases in the lymph nodes had a worse prognosis of disease-free survival compared to patients with negative nodes or LVM. The rate of recurrence was significantly higher for women with micrometastases than those with low-volume metastases (HR = 2.61; p = 0.01). The administration of adjuvant treatment in patients with LVM, without uterine risk factors, remains a matter of debate and requires further evaluation.
KW - endometrial cancer
KW - low-volume metastasis
KW - recurrence-free survival
KW - sentinel lymph node biopsy
KW - ultrastaging
KW - endometrial cancer
KW - low-volume metastasis
KW - recurrence-free survival
KW - sentinel lymph node biopsy
KW - ultrastaging
UR - http://hdl.handle.net/10807/272560
U2 - 10.3390/cancers15072052
DO - 10.3390/cancers15072052
M3 - Article
SN - 2072-6694
VL - 15
SP - N/A-N/A
JO - Cancers
JF - Cancers
ER -